European Union and Business Finland provide Biohit Oyj with a total of EUR 900,000 in financing for product development

Biohit Oyj Press release 8th March 2021 at 10.00 am local time (EET)

Biohit Oyj has received a total of EUR 900,000 in funding from the EU through the Eurostars program and also from Business Finland for the development and launch of rapid tests over the next three years.

The Eurostars program is a joint program of 36 countries managed by the EUREKA Secretariat in Brussels as part of international EUREKA cooperation. The financing of the Finnish parties comes from Business Finland. The funding is a grant primarily to SMEs.

Biohit's CEO Semi Korpela states: “Funding granted by the EU and Business Finland will significantly accelerate product development. The granting of such funding to our company is a testament to the fact that, according to external experts, we are also a major innovator in the field of biotechnology, whose inventions have significant growth potential around the world.”

Additional information: 
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com